soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Oral Semaglutide Lowers Cardiovascular Risk

For group-based comparisons, Kruskal-Wallis analysis of variance (ANOVA) and non-parametric MannWhitney U tests for pairwise group comparisons

Diabetic retinopathy is the most common cause of macular edema, but other conditions can also cause it

L-carnitine affects glycemic markers, hyperglycemia, and insulin resistance ( via a number of different pathways, including the following: (1) Controlling the pyruvate dehydrogenase complex's (PDHC) activity and the intramitochondrial acetyl-CoA/CoA ratio

Sources SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) primary clinical trial reporting GI side-effect rates by dose for tirzepatide

Both are FDA-approved, well-tolerated, and represent major advances in metabolic medicine